Hee‐yeong Kim, Lanxin Zhang, Craig W. Hendrix, Jessica E. Haberer, & Max vonKleist. (2024). Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant. Wiley.
Chicago Style (17th ed.) CitationHee‐yeong Kim, Lanxin Zhang, Craig W. Hendrix, Jessica E. Haberer, and Max vonKleist. Modeling of HIV‐1 Prophylactic Efficacy and Toxicity with Islatravir Shows Non‐superiority for Oral Dosing, But promise as a Subcutaneous Implant. Wiley, 2024.
MLA (9th ed.) CitationHee‐yeong Kim, et al. Modeling of HIV‐1 Prophylactic Efficacy and Toxicity with Islatravir Shows Non‐superiority for Oral Dosing, But promise as a Subcutaneous Implant. Wiley, 2024.
Warning: These citations may not always be 100% accurate.